Trial Profile
A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Adefovir; Entecavir; Granulocyte macrophage colony stimulating factor
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms ANCHOR
- 08 Feb 2022 Results (n=80) assessing the biomarkers associated with a durable functional cure and to dissect the potential immunological mechanisms, published in the Journal of Hepatology.
- 29 Aug 2020 Interim results (n=249) presented at The International Liver Congress 2020
- 24 Oct 2017 Interim results (n=101) assessing virological supression, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.